120 related articles for article (PubMed ID: 11251977)
1. Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model.
Céfai D; Favre L; Wattendorf E; Marti A; Jaggi R; Gimmi CD
Int J Cancer; 2001 Feb; 91(4):529-37. PubMed ID: 11251977
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy.
Céfai D; Schwaninger R; Balli M; Brunner T; Gimmi CD
Cell Death Differ; 2001 Jul; 8(7):687-95. PubMed ID: 11464213
[TBL] [Abstract][Full Text] [Related]
3. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer.
Céfaï D; Morrison BW; Sckell A; Favre L; Balli M; Leunig M; Gimmi CD
Int J Cancer; 1999 Oct; 83(3):393-400. PubMed ID: 10495433
[TBL] [Abstract][Full Text] [Related]
4. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
5. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
[TBL] [Abstract][Full Text] [Related]
6. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
8. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway.
Schillaci R; Salatino M; Cassataro J; Proietti CJ; Giambartolomei GH; Rivas MA; Carnevale RP; Charreau EH; Elizalde PV
J Immunol; 2006 Mar; 176(6):3426-37. PubMed ID: 16517711
[TBL] [Abstract][Full Text] [Related]
9. Activated T cell exosomes promote tumor invasion via Fas signaling pathway.
Cai Z; Yang F; Yu L; Yu Z; Jiang L; Wang Q; Yang Y; Wang L; Cao X; Wang J
J Immunol; 2012 Jun; 188(12):5954-61. PubMed ID: 22573809
[TBL] [Abstract][Full Text] [Related]
10. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
Wigginton JM; Park JW; Gruys ME; Young HA; Jorcyk CL; Back TC; Brunda MJ; Strieter RM; Ward J; Green JE; Wiltrout RH
J Immunol; 2001 Jan; 166(2):1156-68. PubMed ID: 11145697
[TBL] [Abstract][Full Text] [Related]
11. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
12. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A
J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893
[TBL] [Abstract][Full Text] [Related]
14. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
15. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
16. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.
Huber V; Fais S; Iero M; Lugini L; Canese P; Squarcina P; Zaccheddu A; Colone M; Arancia G; Gentile M; Seregni E; Valenti R; Ballabio G; Belli F; Leo E; Parmiani G; Rivoltini L
Gastroenterology; 2005 Jun; 128(7):1796-804. PubMed ID: 15940614
[TBL] [Abstract][Full Text] [Related]
17. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
18. Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?
Allison J; Seino K; Yagita H
Springer Semin Immunopathol; 1998; 19(3):311-22. PubMed ID: 9540159
[No Abstract] [Full Text] [Related]
19. The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.
Priceputu E; Rodrigue I; Chrobak P; Poudrier J; Mak TW; Hanna Z; Hu C; Kay DG; Jolicoeur P
J Virol; 2005 May; 79(10):6377-91. PubMed ID: 15858021
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis-related proteins (Fas, Fas ligand, bcl-2 and p53) in different types of human breast tumors.
Ben-Hur H; Mordechay E; Halperin R; Gurevich P; Zandbank J; Herper M; Zusman I
Oncol Rep; 2002; 9(5):977-80. PubMed ID: 12168058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
